Abstract:Background: To mitigate the cardiotoxicity of anthracycline antibiotics without compromising their anticancer activities is still an issue to be solved. We previously demonstrated that schisandrin B (Sch B) could protect against doxorubicin (Dox)-induced acute cardiotoxicity via enhancing cardiomyocytic glutathione redox cycling that could attenuate oxidative stress generated from Dox. In this study, we attempted to prove if Sch B could also protect against Dox-induced chronic cardiotoxicity, a more clinically relevant issue, without compromising its anticancer activity. Methodology: Rat was given intragastrically either vehicle or Sch B (50 mg/kg) two hours prior to i.p. Dox (2.5 mg/kg) weekly over a 5-week period with a cumulative dose of Dox 12.5 mg/kg. At the 6th and 12th week after last dosing, rats were subjected to cardiac function measurement, and left ventricles were processed for histological and ultrastructural examination. Dox anticancer activity enhanced by Sch B was evaluated by growth inhibition of 4T1, a breast cancer cell line, and S180, a sarcoma cell line, in vitro and in vivo. Principal findings: Pretreatment with Sch B significantly attenuated Dox-induced loss of cardiac function and damage of cardiomyocytic structure. Sch B substantially enhanced Dox cytotoxicities toward S180 in vitro and in vivo in mice, and increased Dox cytotoxcity against 4T1 in vitro. Although we did not observe this enhancement against the implanted 4T1 primary tumor, the spontaneous metastasis to lung was significantly reduced in combined treatment group than Dox alone group. Conclusion: Sch B is capable of protecting Dox-induced chronic cardiotoxicity and enhancing its anticancer activity. To the best of our knowledge, Sch B is the only molecule ever proved to function as a cardioprotective agent as well as a chemotherapeutic sensitizer, which is potentially applicable for cancer treatment.

Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.

Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo

Protective effect of schisandrin B against HK-2 apoptosis induced by Cisplatin

Schisandrin B inhibits cell proliferation and induces apoptosis in human cholangiocarcinoma cells.

Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells.

Prevention Effects of Schisandrin B on Cardiotoxicity Induced by Anthracyclines in Rabbit Model

Mechanism Study of Doxorubicin-schisandrin B Co-delivery Liposomes to Overcome Multidrug Resistance

Prevention Against and Treatment of Doxorubicin-Induced Acute Cardiotoxicity by Dexrazoxane and Schisandrin B

Schisandrin B enhances doxorubicin-induced apoptosis in SMMC7721 cell line

Schisandrin B Antagonizes Cardiotoxicity Induced by Pirarubicin by Inhibiting Mitochondrial Permeability Transition Pore (mPTP) Opening and Decreasing Cardiomyocyte Apoptosis

Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1.

Schisandrin B--a novel inhibitor of P-glycoprotein.

Reducing oxidative stress may be important for treating pirarubicin-induced cardiotoxicity with schisandrin B

Schisandrin B Prevents Doxorubicin-induced Cardiotoxicity in Rabbits

Scutellarin Attenuates Doxorubicin‐Induced Cardiotoxicity by Inhibiting Myocardial Fibrosis, Apoptosis and Autophagy in Rats

Schisandrin B protects against nephrotoxicity induced by cisplatin in HK-2 cells via Nrf2-ARE activation

Schisandrin B protects against angiotensin II-induced endotheliocyte deficits by targeting Keap1 and activating Nrf2 pathway.

Prevention And Treatment Of Doxorubicin-Induced Cardiotoxicity By Dexrazoxane And Schisandrin B In Rabbits

Schisandrin A Enhances the Cytotoxicity of Doxorubicin by the Inhibition of Nuclear Factor-Kappa B Signaling in a Doxorubicin-Resistant Human Osteosarcoma Cell Line

Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy

Prevention of Doxorubicin Cardiopathic Changes by a Benzyl Styryl Sulfone in Mice.